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Pancreatic deletion of the interleukin-1 receptor
disrupts whole body glucose homeostasis and
promotes islet b-cell de-differentiation
Susan J. Burke 1, Heidi M. Batdorf 1, David H. Burk 1, Thomas M. Martin 1, Tamra Mendoza 1,
Krisztian Stadler 1, Wateen Alami 2, Michael D. Karlstad 2, Matthew J. Robson 3, Randy D. Blakely 4,
Randall L. Mynatt 1, J. Jason Collier 1,*
ABSTRACT
Objective: Pancreatic tissue, and islets in particular, are enriched in expression of the interleukin-1 receptor type I (IL-1R). Because of this
enrichment, islet b-cells are exquisitely sensitive to the IL-1R ligands IL-1a and IL-1b, suggesting that signaling through this pathway regulates
health and function of islet b-cells.
Methods: Herein, we report a targeted deletion of IL-1R in pancreatic tissue (IL-1RPdx1L/L) in C57BL/6J mice and in db/db mice on the C57
genetic background. Islet morphology, b-cell transcription factor abundance, and expression of the de-differentiation marker Aldh1a3 were
analyzed by immunofluorescent staining. Glucose and insulin tolerance tests were used to examine metabolic status of these genetic manip-
ulations. Glucose-stimulated insulin secretion was evaluated in vivo and in isolated islets ex vivo by perifusion.
Results: Pancreatic deletion of IL-1R leads to impaired glucose tolerance, a phenotype that is exacerbated by age. Crossing the IL-1RPdx1L/L
with db/db mice worsened glucose tolerance without altering body weight. There were no detectable alterations in insulin tolerance between IL-
1RPdx1L/Lmice and littermate controls. However, glucose-stimulated insulin secretion was reduced in islets isolated from IL-1RPdx1L/L relative
to control islets. Insulin output in vivo after a glucose challenge was also markedly reduced in IL-1RPdx1L/Lmice when compared with littermate
controls. Pancreatic islets from IL-1RPdx1L/L mice displayed elevations in Aldh1a3, a marker of de-differentiation, and reduction in nuclear
abundance of the b-cell transcription factor MafA. Nkx6.1 abundance was unaltered.
Conclusions: There is an important physiological role for pancreatic IL-1R to promote glucose homeostasis by suppressing expression of
Aldh1a3, sustaining MafA abundance, and supporting glucose-stimulated insulin secretion in vivo.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Pancreatic islet b-cells secrete insulin in response to fuel stimuli, with
glucose regarded as the primary trigger for hormone release [1]. The
mature, adult b-cell expresses a multitude of transcription factors (TFs)
responsible for maintaining a robust insulin secretory phenotype.
Representative examples of such regulatory TFs in b-cells include
MafA, Nkx6.1, and Pdx-1. Indeed, Pdx-1 is important for pancreas
development and remains expressed in pancreatic b-cells to sustain
insulin production [2]; reductions in Pdx-1 impair glucose-stimulated
insulin secretion [3]. Nkx6.1 is important for suppression of the
glucagon gene and together MafA and Nkx6.1 support glucose-
stimulated insulin secretion [4,5]. Several of these TFs are either
reduced in abundance or in nuclear presence in mouse models of
obesity and in humans with obesity and T2D [6e8]. In addition,
Aldh1a3 has recently been associated with de-differentiation of b-
cells, helping to explain reduced insulin secretion in both rodents and
humans [9,10].
Obesity correlates with increased pancreatic islet size [11e13], while
inflammation is linked with reductions in b-cell function and mass in
both type 1 (T1D) and type 2 diabetes (T2D) [14,15]. A variety of in-
flammatory stimuli, including free fatty acids and cytokines, have been
associated with tissue dysfunction during progression to metabolic
disease. For example, elevated levels of interleukin-1b promote key
signaling changes within adipose tissue [16], liver [17], and pancreatic
islets [18,19]. The cytokines IL-1a and IL-1b signal through the
interleukin-1 receptor type I [20]. These two cytokines are opposed by
the interleukin-1 receptor antagonist protein, encoded by the IL-1RN
gene [21]. The type II interleukin-1 receptor is proposed to function
as a decoy receptor, able to bind ligands, but not communicate an
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Figure 1: Interleukin-1 signaling in b-cells potentiates insulin secretion acutely but restricts insulin secretion over time, with nitric oxide functioning as a negative feedback signal. (A) Insulin secretion in cultured 832/13 rat b-
cells normalized as percent of the maximal stimulated response after no treatment (NT), or 30 min incubations in either 1 ng/mL IL-1b or 40 ng/mL TNF-a (n ¼ 4, some of which were performed in duplicate or triplicate). (B) Dose response of
IL-1b and TNF-a on a 5x NF-kB promoter luciferase reporter gene in cultured 832/13 rat b-cells; luciferase output is normalized to total cellular protein and shown as fold over the unstimulated control cells (n ¼ 4). (C) Insulin secretion in
cultured 832/13 rat b-cells normalized as percent of the maximal stimulated response after overnight exposure to either 0.1 and 1 ng/mL IL-1b or 20 and 40 ng/mL TNF-a versus cells left untreated (NT; n ¼ 3, some of which were conducted in
duplicate). (D) Total nitrite accumulation in the media in response to the indicated doses of IL-1b or TNF-a (n ¼ 3). (E) Electron paramagnetic resonance spin trapping measurements of nitric oxide radical in response to the indicated doses of IL-
1b or TNF-a (n ¼ 3). (F) Insulin secretion in cultured 832/13 rat b-cells normalized as percent of the maximal stimulated response to show the marked reduction in insulin secretion by overnight exposure to 1 ng/mL IL-1b versus the dose-
dependent recovery of insulin secretion by L-NMMA (n ¼ 3). (G) Fold increase in total nitrite production in 832/13 cells by exposure to 1 ng/mL IL-1b overnight and the dose-dependent reduction by L-NMMA (n ¼ 3). Error bars represent SEM. *,










































Figure 2: Deletion of the IL-1R in pancreatic tissue impairs IL-1b signaling in islets in vivo. (A) and (B) Islets were isolated from mice of the indicated genotype and expression of the Il1r and cre genes determined by real-time PCR
analyses (n ¼ 4). (C) Mice were injected with either saline (CLow and CHi), 1 (IL-1bLow) or 3 (IL-1bHi) mg/kg body weight of IL-1b. Lysate from homogenized liver was used to blot for phospho- and total JNK. Histone H3 is shown as a loading








































intracellular signal [22]. Collectively, these genes and the proteins they
encode are part of the IL-1 signaling system, which is associated with
both acute and chronic inflammatory events [23].
Intriguingly, IL-1b has been shown to potentiate glucose-stimulated
insulin secretion acutely [24,25], but impair insulin secretion when
b-cells are chronically exposed [26]. Using mouse, rat, and human
islets as well as rodent and human derived b-cell lines, we and others
have studied the impact of IL-1 signaling on insulin secretion and a
variety of other parameters [8,27e32]. While a wealth of information
on the IL-1 signaling pathway has been gained via these in vitro
studies, the pancreas specific role of this pathway in vivo, especially as
a homeostatic regulator of metabolism, is not entirely clear.
To our knowledge, we describe herein the first conditional deletion of
the IL-1R in pancreatic tissue and the subsequent impact of this
deletion on islet function and whole body glucose homeostasis. Several
key findings emerged from these studies. 1) In the absence of
pancreatic IL-1R signaling, glucose tolerance is impaired, a phenotype
that worsens with age and is exacerbated with obesity. 2) Insulin
secretion in vivo and ex vivo is diminished in IL-1RPdx1L/L when
compared with littermate control mice. 3) MafA abundance is reduced
in islets from IL-1RPdx1L/L mice. 4) There is enhanced expression of
Aldh1a3, a newly described marker associated with cellular de-
differentiation, in the islets of IL-1RPdx1L/L mice.
2. METHODS
2.1. Cell Culture, luciferase assays, and reagents
832/13 rat insulinoma cells were cultured as described previously [33].
Mouse and rat IL-1b and TNFa were from Peprotech (Rocky Hill, NJ).
NG-monomethyl-L-arginine (L-NMMA) was from Cayman Chemical
(Ann Arbor, MI). 832/13 cells were grown in 24-well plates, transduced
with the 5x NF-kB luciferase adenovirus and treated as described in
the legend to Figure 1. Following treatment, cells were lysed in 1x
Passive Lysis Buffer (Promega; Madison, WI) and promoter luciferase
activity was measured using the Luciferase Assay System (Promega)
on a GloMax luminometer (Promega). Luciferase activity was
normalized to total protein content determined via BCA assay.
2.2. Nitrite determination, glucose stimulated insulin secretion
(GSIS), and electron paramagnetic resonance spectroscopy (EPR)
832/13 cells were grown in 12-well plates. Nitrite in the cell culture
media was measured using the Griess assay kit from Promega. GSIS
assays were performed as described previously [34], with secreted
insulin detected using the Rat Insulin ELISA from Mercodia (Uppsala,
Sweden). In addition, cells were lysed with M-PER lysis reagent
(Thermo Fisher Scientific, Waltham, MA) to quantify total intracellular
protein content by BCA assay (Thermo Fisher Scientific). The spin trap
N-methyl-D-glucamine dithiocarbamate (MGD) was purchased from
ENZO Life Sciences and used to detect nitric oxide by EPR spectros-
copy [8,35]. The N-methyl-D-glucamine dithiocarbamateeiron com-
plex ((MGD)2-Fe2þ) was prepared fresh for each experiment by
making stock solutions of 500 mM MGD and 100 mM Fe2þ (from
FeSO4.7H2O) in ultrapure water under anaerobic conditions. A final
concentration of 25 mM MGD and 5 mM Fe2þ was introduced onto
cells in serum free media for 30 min, followed by collection of su-
pernatants for the measurements of the (MGD)2-iron-NO complex. All
EPR measurements were conducted using a quartz flat cell at room
temperature in a Bruker EMX Plus spectroscope. Typical instrumental
conditions were 20 mW microwave power, 5.0 G modulation ampli-
tude, 1  105 gain, 0.163 s time constant and 80 G scan range.
Quantitation was carried out by measuring and comparing the first
peak heights on the spectra.
2.3. Experimental animals
Mice with a pancreas-specific deletion of IL-1R were generated by
crossing IL-1R floxed mice [36] with Pdx1-Cre mice (Stock # 014647;
The Jackson Laboratory, Bar Harbor, Maine). db/þ mice (Stock #
00697; The Jackson Laboratory) were crossed with IL-1RPdx1/
mice to generate db/þfl/fl and db/þPdx1þ/ mice. These heterozy-
gous mice were then bred with each other to generate db/dbfl/fl and
db/dbPdx1/ mice. Mice were housed with a 12-hour light/12-hour
dark cycle at 22  1 C and given access to Lab Diet 5001 (Purina)
ad libitum throughout the study. For confirmation of IL-1R knock-
down, a cohort of 12 week old IL-1Rfl/fl and IL-1RPdx1/ mice
received a single intraperitoneal injection of saline or IL-1b at a
concentration of either 1 mg/kg or 3 mg/kg body weight. Animals
were sacrificed 30 min post-injection for histological or immunoblot
analysis. Non-fasting blood glucose measurements were taken using
the Bayer Breeze 2 Glucometer (Bayer HealthCare LLC, Mishawaka,
IN). Measurements of body mass and composition (fat, lean, and fluid
mass) were assessed by NMR using a Bruker Minispec LF110 Time-
Domain NMR system. Upon completion of the study, animals were
fasted for 2 h, anesthetized by CO2 asphyxiation then euthanized by
decapitation. Liver tissue was snap frozen in liquid nitrogen, and
pancreata were fixed in 10% neutral-buffered formalin. Trunk blood
was harvested, and the serum fraction was collected. For all ex-
periments, littermates were used as controls with three to four
separate cohorts of mice bred to complete the study. All animal
procedures were approved by both the Pennington Biomedical
Research Center and University of Tennessee Institutional Animal
Care and Use Committees.
2.4. GTT, ITT, ex vivo and in vivo GSIS
Glucose tolerance tests were performed in male and female IL-
1RPdx1/ and littermate control mice following a 4 h fast. Mice were
intraperitoneally injected with glucose at 2.5 g/kg body weight.
Glucose tolerance tests in db/dbfl/fl and db/dbPdx1/ mice were
performed by i.p. injection of glucose at 1.25 g/kg body weight
following a 4 h fast. Blood samples were taken from the tail vein at 0,
20, 40, 60, and 120 min after injection and blood glucose was
determined with an Alphatrak 2 Glucometer (Zoetis, Kalamazoo, MI).
An insulin tolerance test was performed in male and female IL-
1RPdx1/ and littermate control mice after a 2 h fast. Animals were
intraperitoneally injected with Humulin R insulin (Lilly, Indianapolis, IN)
at 1.0 U/kg body weight. Blood glucose measurements were taken
from the tail vein at 0, 15, 30, 45, 60, and 90 min after injection. Blood
glucose levels were plotted against time, and the area under the curve
was calculated. For in vivo measurements of GSIS, animals were
fasted for 4 h, followed by collection of blood via the submandibular
vein for baseline measurements of insulin (time ¼ 0 min). Mice were
then i.p. injected with glucose at 2.5 g/kg body weight, followed by a
second submandibular blood collection 10 min post-injection. Peri-
fusion analyses of insulin secretion using isolated islets of similar size
were performed as described previously [37]. Briefly, islet perifusion
was conducted by placing islets into a 1-mL glass column, in which
each of four distinct channels were operated by high-precision peri-
staltic pump. Perifusion media and islet chambers were maintained at
37 C using a large-capacity water bath with fractions collected over
time. Islets were sized matched from each animal for the comparisons
within and between genotypes.
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Figure 3: Deletion of the IL-1R in pancreatic tissue impairs reduces glucose tolerance in older female mice. (A) Body mass, (B) fat mass, (C) lean mass, and (D) fluid mass of female mice in three month intervals (n ¼ 8e13). Glucose
tolerance tests (GTT) conducted in (E) two month, (F) nine month, and (G) twelve month old female mice (n ¼ 8e13). (H) Area under the curve calculations for each GTT. (I) The percentage of islet fraction, defined as (total islet area/total
pancreatic area) x 100. (J) Insulin positive area (square microns) within the islet across the indicated ages. (K) Serum insulin at the indicated ages and genotypes (n ¼ 8e13). White bars indicate littermate controls while black bars represent IL-








































Figure 4: Deletion of the IL-1R in pancreatic tissue impairs reduces glucose tolerance in young male mice, a phenotype which is exacerbated with age. (A) Body mass, (B) fat mass, (C) lean mass, and (D) fluid mass of male mice.
Glucose tolerance tests (GTT) conducted in (E) nine week, (F) six month, and (G) nine month old male mice (n ¼ 8e15). (H) Area under the curve calculations for each GTT. (I) Insulin tolerance test (ITT) at four months of age with AUC inset











































2.5. Serum ELISA and total acyl glycerol measurements
Serum insulin was measured using the Mouse Insulin ELISA kit from
Mercodia. Mouse Proinsulin ELISA and Mouse C-peptide ELISA kits
were from Alpco (Salem, NH). For acyl glycerol measurements, 30 mg
of isolated liver tissue was homogenized in 300 mL 5% NP-40 solution
and heated twice to 95 C to solubilize all acyl glycerol species.
Samples were centrifuged at 4 C on maximum speed for 2 min, and
the supernatant was transferred to a clean, pre-chilled tube. The
samples were diluted 10-fold for use with the Triglyceride Determi-
nation kit from Sigma Aldrich (St. Louis, MO). Kit protocols were used
for all measurements.
2.6. Mouse islet isolation, total RNA extraction, cDNA synthesis,
and real-time RT-PCR
Mouse islets were isolated from 8 week old IL-1RPdx1/ and litter-
mate controls as described previously [38]. Islets were also isolated
from 8-week-old male db/þ and db/db mice (B6.BKS(D)-Leprdb/J;
stock number 00697) acquired from the Jackson Laboratories.
Extraction of RNA, cDNA synthesis, and transcript analysis have been
described in detail previously [7,39].
2.7. Tissue protein isolation and immunoblotting
Isolated liver tissue (50 mg) was homogenized in 500 mL T-PER lysis
reagent (Thermo Fisher Scientific) supplemented with Halt Protease
and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Protein
was quantified using a BCA assay. Denaturation of samples and
immunoblotting conditions have been described [40]. Antibodies were
from Cell Signaling Technology.
2.8. Islet histology and immunohistochemistry
Our methods for sectioning, embedding, and measuring insulin-
positive area have been described previously [41]. Antibodies used
were as follows: Nkx6.1 (Developmental Studies Hybridoma Bank
#F55A12; 1:100 dilution overnight at 4 C), Pdx-1 (Cell Signaling
#5679; 1:300 dilution overnight at 4 C), MafA (LSBio# LS-C286590;
1:75 dilution overnight at room temperature), Insulin (Dako # A0564),
Foxo1 (Cell Signaling #2880; 1:50 dilution overnight at room tem-
perature), p65 (Cell Signaling # 8242; 1:1000 dilution for 2 h at room
temperature) and Glucagon (Cell Signaling #2760; 1:300 dilution
overnight at 4 C). All antibodies were detected with either Alexa Fluor
secondary conjugation (Alexa 488, Alexa Fluor Plus 555), except for
Nkx6.1, which was detected using a biotin/streptavidin exposure
method, and, Foxo1, which was detected using a Perkin Elmer TSA
Cy3 kit.
2.9. Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 (GraphPad
Software, La Jolla, CA). Data were analyzed by either one-way ANOVA
using a Tukey post hoc, repeated measures ANOVA (for longitudinal
measures of blood glucose, body weight, and body composition), or
two-tailed Student’s t-test. Data are presented as means  SEM.
3. RESULTS
3.1. Interleukin-1 signaling in b-cells potentiates insulin secretion
acutely but restricts insulin secretion over time, with nitric oxide
functioning as a negative feedback signal
IL-1b has both positive and negative effects on insulin secretion, and
these outcomes are dependent on duration of b-cell exposure to the
cytokine. Using 832/13 rat b-cells, we found that inclusion of IL-1b in
the culture media enhanced glucose-stimulated insulin secretion by
27% (Figure. 1A). TNF-a did not recapitulate this effect (Figure 1A),
indicating the IL-1 effect is not simply a global response to inflam-
matory signals, since both cytokines induce robust NF-kB transcrip-
tional activity (Figure 1B). Conversely, overnight exposure to IL-1b, but
not TNF-a, reduced insulin secretion in response to glucose
(Figure 1C). Nitrite, an index of nitric oxide production, accumulates in
response to IL-1b but not to TNF-a (Figure 1D). Using spin trapping
coupled with electron paramagnetic resonance spectroscopy, we
found that nitric oxide production is selectively driven by IL-1b but not
by TNF-a (Figure 1E). Moreover, insulin secretion in the presence of IL-
1b could be recovered (Figure 1F) when nitrite production was limited
by the broad spectrum NOS inhibitor L-NMMA (Figure 1G). Thus, IL-1b
potentiates insulin secretion during acute exposure, but promotes nitric
oxide accumulation as a negative feedback regulator to constrain in-
sulin secretion following chronic exposure to the stimulus.
3.2. Deletion of the IL-1R in pancreatic tissue impairs whole body
glucose tolerance in young and old male mice, but has only
marginal impact in aged female mice
Because IL-1b signaling is capable of both enhancing and impairing
insulin secretion (Figure 1 and [24,25,42]), we generated a pancreatic
specific deletion of the IL-1 receptor (IL-1R) to investigate the in vivo
metabolic consequences associated with disrupting this pathway. This
was accomplished by crossing IL-1R ‘floxed’ mice with mice
expressing cre recombinase driven by the Pdx-1 promoter (IL-
1RPdx1L/L). The expression of the IL-1R gene is reduced by 93% in
islets isolated from IL-1RPdx1L/L mice relative to floxed control mice
(Figure 2A). This reduction is congruent with strong expression of the
cre transgene (Figure 2B). Cre expression was not detected in other
tissues assessed (not shown), consistent with selectivity of IL-1R
deletion (Figure 2C). To assess the functional consequence of this
deletion, we injected mice with IL-1b. IL-1R signaling was similar in
liver tissue of both control mice and IL-1RPdx1L/L mice (Figure 2D).
By contrast, p65 translocation is reduced in pancreatic islets of IL-
1RPdx1L/L mice injected with IL-1b, but not in littermate control mice
(Figure 2E). Upon quantification of multiple islets, we observed p65
abundance in 78% of nuclei from IL-1b injected floxed control mice
(representative image in upper right panel of Figure 2E) versus 23% of
nuclei in IL-1b injected IL-1RPdx1L/L mice (image in lower right panel
of Figure 2E). In mice receiving saline control injections, only 9% of
nuclei from floxed control and 10% of nuclei in IL-1RPdx1L/L mice
displayed nuclear p65 localization.
Female IL-1RPdx1L/L and littermate control mice had similar body
compositions up to one year of age (Figure 3A e D). Young female
mice (12 weeks of age) display no alterations in glucose tolerance due
to deletion of the IL-1R in pancreatic tissue (Figure 3E) and even older
females (nine months) are still near control values (Figure 3F). How-
ever, by one year, there appears to be a modest shift in glucose
tolerance in IL-1RPdx1L/L mice relative to floxed control mice
(Figure 3G), although the area under the curve measurement is not
altered (Figure 3H). The islet fraction is not significantly different be-
tween IL-1RPdx1L/L mice and control mice (Figure 3I). Insulin positive
area is modestly increased in older IL-1RPdx1L/L mice (12 months;
Figure 3J), while serum insulin is not different from control mice
(Figure 3K).
Similar to observations in female mice, there are no growth or body
composition differences between male IL-1RPdx1L/L mice when
compared with littermate control mice, reflected by similar body, fat,
lean, and fluid mass composition (Figure 4AeD). However, in male
mice, there is clear glucose intolerance at nine weeks of age (Figure 4E)
that is exacerbated at both six (Figure 4F) and nine months of age
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(Figure 4G). Area under the curve changes at each age are shown in
Figure 4H. Insulin tolerance tests were similar between IL-1RPdx1L/L
mice and littermate control mice (Figure 4I and AUC inset), indicating
that changes insulin sensitivity are not driving reduced glucose tolerance
in IL-1RPdx1L/L mice. We note that insulin positive area is reduced in
IL-1RPdx1L/L mice by six months of age (Figure 4J). This results in
diminished islet area relative to pancreatic area in the IL-1RPdx1L/L
mice when compared with littermate controls (Figure 4K).
3.3. IL-1RPdx1L/L mice display reduced glucose-stimulated
insulin secretion ex vivo and after a glucose challenge in vivo
Serum insulin levels are similar between IL-1RPdx1L/L and littermate
control mice (Figure 5A). In addition, the proinsulin/C-peptide ratio,
which has been used to indicate ER function [43], is also similar be-
tween groups (Figure 5B). Because insulin tolerance was similar be-
tween IL-1RPdx1L/L mice and littermate controls (Figure 4I), but
glucose tolerance was impaired (Figure 4EeG), we next investigated
insulin output after a glucose challenge in vivo. We found that insulin
secretion in IL-1RPdx1L/L mice was decreased by 56% when
compared with littermate controls 10 min after a glucose bolus
(Figure 5C). Consistent with these results, perifusion analyses on
isolated islets revealed a decrease in both glucose-stimulated and KCl-
induced insulin release (Figure 5D). Quantification of peak glucose-
stimulated insulin secretion revealed 25% less output in IL-1RPdx1L/
L mice relative to littermate controls (solid arrow in Figure 5D re-
plotted in Figure 5E). Similarly, there was a 38% decrease in KCl-
induced insulin secretion (dashed arrow in Figure 5D re-plotted in
Figure 5F). These results may be due, at least in part, to the 22%
reduction in insulin content in islets from the IL-1RPdx1L/L mice
(Figure 5G).
3.4. Increased expression of the de-differentiation marker Aldh1a3
in islets with pancreatic deletion of IL-1R
Aldh1a3 expression is elevated in rodent models of obesity and
diabetes [7,9] and in islets from humans with T2D [10]. Because
glucose intolerance typically precedes onset of T2D, and IL-
1RPdx1L/L mice display impaired glucose tolerance (Figure 5), we
investigated islet histology in an effort to understand the underlying
Figure 5: IL-1RPdx1L/L mice display reduced glucose-stimulated insulin secretion in isolated islets and after a glucose challenge in vivo. (A) Serum insulin at each age
and genotype (n ¼ 6e10). (B) Serum proinsulin/C-peptide ratio. (C) Serum insulin at baseline (time 0) and 10 min after i.p. injection of glucose (2.5 g/kg body weight; n ¼ 6e8).
(D) Perifusion analysis from isolated islets (n ¼ 7e8). (E) Peak glucose-stimulated insulin output from the graph in (D; solid arrow). (F) Peak KCl-induced insulin secretion from the
graph in (D; dashed arrow). (G) Insulin content per 50 size-matched islets. #, p < 0.1; *, p < 0.05; **, p < 0.01.
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phenotype. Glucagon was expressed normally within the islets of
both IL-1RPdx1L/L mice and littermate controls (Figure 6A). How-
ever, aldh1a3 levels were clearly elevated (Figure 6B). Foxo1 staining
trended towards increased nuclear abundance within the islets of IL-
1RPdx1L/L mice when compared with littermate controls (images in
Figure 6C) although this was heterogeneous; quantification of mul-
tiple islets per mouse indicated 43% nuclear localization in IL-
1RPdx1L/L mice and 35% Foxo1 nuclear abundance in littermate
controls. Much more obvious was that IL-1RPdx1L/L mice had 39%
of their nuclei positive for MafA while the littermate control mice
displayed 72% nuclear positivity for this transcription factor (images
in Figure 6D). The nuclear abundance of Nkx6.1 and Pdx-1 were
unaltered between genotypes (Figure 6E,F). Collectively, we interpret
this data to indicate that signaling through the IL-1R influences islet
health and function.
3.5. Deletion of IL-1R in pancreatic tissue of db/db mice worsens
glucose tolerance without altering body weight
The db/db mouse model displays markers of pancreatic islet
inflammation (see ref. [38] and Figure 7A). To test the hypothesis that
reducing IL-1 signaling would alleviate inflammation-induced islet
dysfunction and thus improve glucose homeostasis, we generated
db/db mice with pancreatic deletion of IL-1R (db/db Pdx1L/L). The
db/db Pdx1L/L mice grow normally and have similar total body mass
(Fig. 7B), fat mass (Figure 7C), and lean mass (Figure 7D) as their
littermate controls. While blood glucose levels over an eight week
period trend higher in the db/db Pdx1L/L mice (Figure 7E), glucose
intolerance is clearly exacerbated in db/db Pdx1L/L mice
(Figure 7F,G). Insulin positive area (Figure 7H) is reduced in the db/db
Pdx1L/L mice relative to the littermate control mice, while islet
fraction (Figure 7I) trends lower. Accordingly, circulating insulin was
also consistently lower in db/db Pdx1L/L mice (Figure 7J). However,
there were no differences in either total pancreatic mass or the mass
of individual pancreatic sections (Figure 7K). In addition, total lipid
content, measured as acyl glycerols, were not different between the
genotypes (Figure 7L). Taken together, we interpret this data to
indicate that pancreatic IL-1R is necessary to sustain insulin pro-
duction in states of obesity and insulin resistance and its absence
worsens glucose homeostasis in db/db mice.
4. DISCUSSION
We have generated two novel mouse models reported herein, which
have revealed an important physiological role for IL-1 receptor
Figure 6: Increased expression of the de-differentiation marker Aldh1a3 in islets with pancreatic deletion of IL-1R. Triple-fluorescence staining of fixed pancreatic tissue
showing insulin (green) and DAPI (blue). In all panels, littermate controls (n ¼ 6) are on the left while islets from IL-1RPdx1/ mice (n ¼ 5) are on the right hand side. The red stain
indicates (A) glucagon, (B), Aldh1a3, (C), FOXO1, (D) MafA, (E) Nkx6.1, and (F) Pdx-1.Note the orange staining within the islet in panel (B) from IL-1RPdx1/ mice, indicating
increased aldh1a3 in b-cells. Note the reduction in MafA nuclear abundance in panel (D) in IL-1RPdx1/ mice.
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Figure 7: Deletion of IL-1R in pancreatic tissue ofdb/dbmiceworsens glucose tolerancewithout changingbodyweight. (A) Expression of the Il1a and Il1b genes in islets isolated from
eight week old db/þ and db/dbmice (n¼ 4e8). (B) Total bodymass, (C) fatmass, and (D) leanmass of db/dbf l/fl and db/db Pdx1/mice (n¼ 9). (E) Blood glucosemeasured over 6e14weeks
of age (n¼ 9). (F) Glucose tolerance test conducted in 10week oldmice (1.25 g/kgbodyweight; n¼ 9). (G) Area under the curve analysis of the GTT shown in (F). (H) Insulin positive area (square
microns) and (I) Islet fraction (total islet area/total pancreatic area) x 100. (J) Fasting serum insulin in 14week oldmice (n¼ 9). (K) Pancreasweight (L) Pancreas TG. #, p< 0.10; *, p< 0.05; ****,
p < 0.001.
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signaling in pancreatic tissue. The IL-1R signaling system clearly
contributes to whole-body glucose homeostasis by maintaining the
health and function of islet b-cells. Indeed, in the absence of
pancreatic IL-1R signaling, whole body glucose homeostasis is dis-
rupted in lean mice and worsened in genetically obese db/db mice.
Reduced insulin output in response to a glucose challenge was
observed in both in vivo and ex vivo analyses. Intriguingly, this
observation may be more important in male mice, as female mice
were only impacted to a minor degree by this deletion and only at
advanced age. With IL-1 signaling typically studied from a patho-
logical viewpoint, our present work offers new insights into the
physiological relevance of this pathway and illustrates that it may also
include a gender specific effect. The sex differences reported here
may have relevance to future design of human clinical trials targeting
the IL-1 signaling pathway.
Targeting inflammation to treat metabolic diseases, including T2D, is
an emerging theme in both basic and clinical studies. Opinions on this
topic range from enthusiastic [44] to more skeptical [45]. In our view, a
major impediment to development of targeted clinical therapeutics is a
full understanding of both the physiological and pathological roles for
cytokine and other inflammation-based signaling pathways. For
example, therapeutics targeting the IL-1 system have been under-
whelming in terms of clinical outcomes [46] and fail to prevent auto-
immune destruction of islets using whole body gene deletion
approaches [47]. In addition, mice with global deletion of the IL-1R
display reduced sensitivity to leptin and are more susceptible to
becoming obese with age [48]. Alternatively, systemic approaches
targeting IL-1b in GK rats, a model of T2D, showed reduced inflam-
mation in liver and improved insulin sensitivity [49]. Furthermore, acute
increases in IL-1 signaling enhance insulin secretion (Figure 1A) while
chronic activation of this pathway reduces insulin output (Figure 1C),
consistent with other studies conducted in vitro [24,25,50]. Conse-
quently, tissue specific approaches, such as shown herein for
pancreatic IL-1R deletion, now provide critical insights into physio-
logical IL-1 signaling in vivo.
Recently, Boni-Schnetzler and colleagues demonstrated that deletion
of the IL-1R antagonist protein allows enhanced signaling through the
IL-1R pathway, which impairs b-cell proliferation [51]. These results
are in agreement with in vitro studies showing decreased incorpo-
ration of radiolabeled nucleotides into DNA (an index of proliferation)
in the presence of IL-1 pathway activation [8]. From a physiological
perspective, postprandial elevations in IL-1 support glucose disposal
[52]. Thus, while too much IL-1 signaling is detrimental to b-cell
health [8,29,51], limiting physiological IL-1 signaling reduces
glucose tolerance (Figure 4EeG) without impairing insulin sensitivity
(Figures 4I). Accordingly, IL-1R signaling plays an important role in
the overall metabolic health of the islet b-cells (Figure 5). Our results
are consistent with recent studies using both mouse and human
islets ex vivo, where IL-1 signaling enhances docking of insulin
granules, supporting a physiological role for IL-1R activation to fine
tune b-cell function [25]. From a translational perspective, the ability
of IL-1 to potentiate glucose-stimulated insulin secretion increases
with BMI, but is lost or markedly reduced in the islets from T2D
patients [25].
Insulin production is impaired in the Csf1op/Csf1op mouse model [53],
which has a severely diminished macrophage population. Taken
together with our results herein, macrophage derived IL-1 is likely to be
critical to support islet b-cell health, including sustained MafA abun-
dance, maintenance of the differentiated state, and preservation of
secretory function. If true, this would explain why therapies targeting the
IL-1 signaling pathway have shown either mixed results or limited
efficacy during clinical trials. Indeed, macrophages and b-cells clearly
have a symbiotic relationship, with macrophages responding to ATP
release from b-cells and b-cells responding to cytokines produced and
secreted by macrophages [54,55].
In our view, b-cells use nitric oxide in a physiological feedback loop to
limit insulin secretion, which fits with IL-1 having both potentiating and
suppressor activities in insulin secretion assays. The gene encoding the
inducible nitric oxide synthase (iNOS) enzyme is robustly responsive to
cytokines in pancreatic b-cells [56,57]. This elevation in iNOS enzyme
abundance promotes nitric oxide accumulation, which limits calcium
responses from intracellular sources [8] and inhibits mitochondrial
aconitase activity [58]. Collectively, these outcomes reduce insulin
secretion. We posit that nitric oxide buildup, and subsequent reduction in
insulin secretion, prevents hypoglycemic effects that would otherwise
occur with exaggerated insulin secretory responses by potentiating
agents (in this case IL-1). Nitric oxide is an ideal signal for this purpose
due its short lived nature and ability to be quickly synthesized by the
iNOS enzyme. Any impact nitric oxide has to damage DNA or become
toxic is subject to repair systems present in b-cells [59].
In addition, the ability of IL-1 to enhance chemokine secretion, an event
independent of cellular nitric oxide levels [8], is an important commu-
nication system with the islet resident macrophages. Interestingly, these
macrophages appear to stay in an activated state, which may be distinct
frommacrophages in other tissues, e.g., lung, where the resting or basal
state is the default [60]. The ability of islet macrophages to stay in an
‘activated’ state (relative to other tissue resident macrophages) may thus
provide sufficient IL-1 to support physiological health of pancreatic b-
cells. Indeed, in the absence of pancreatic IL-1R signaling, insulin
content is reduced (Figure 5G), expression of MafA diminishes while
Aldh1a3 is elevated (Figure 6), providing an explanation for reduced
glucose tolerance (Figure 4EeH). This is significant because reduced
insulin content and elevated Aldh1a3 expression are features of failing
b-cells in both rodent [7,9] and human T2D [10].
We suspect that the upregulation of the IL-1R ligands in db/dbmice [38],
ZDF rats [8,61], and obese humans [25,62] is a compensatory response
intended to sustain insulin production and secretion. These phenotypes
are lost in the absence of pancreatic IL-1R signaling, further deterio-
rating glucose homeostasis (Figure 7F& 7G). The presence of Aldh1a3
within the islets of lean IL-1RPdx1L/L mice likely indicates extreme
stress within the islet (e.g., compensation for age induced insulin
resistance) and/or diminished ability to respond to metabolic needs with
compensatory insulin output. The deletion of multiple Foxo1 proteins,
severe obesity, or deletion of Abcc8, a crucial component of the b-cell
KATP eregulated ion channel, all promote increased expression of
Aldh1a3 [7,9,63]. Thus, Aldh1a3 appears to be a solid indicator of
reduced b-cell health, decreased mature b-cell number, or both.
In summary, our present study supports the interpretation that IL-1
receptor signaling has important physiological functions in pancre-
atic islets. Further studies will address islet b-cell specific deletion as
well as include the use of inducible deletion of IL-1R in the adult mouse
to account for any potential developmental effects that may have
occurred in the present model. Based on these data, the timing and
context of any specific therapeutic intervention targeting IL-1 ligands or
the IL-1R will need to be carefully evaluated to elicit the desired
salutary response without disrupting important physiological mecha-
nisms associated with this pathway. Our observations may also help to
explain why anti-inflammatory approaches do not always provide the
expected or preferred beneficial outcome in the obese and diabetic
populations. These results also provide compelling reasons to further
examine gender specific outcomes relevant to IL-1 signaling in
pancreatic tissue. Therefore, a more comprehensive understanding of
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individual signaling pathways, in both physiological and pathological
frameworks, is required to provide the next generation of targeted
therapeutic approaches.
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